Asset Visibility: Pharma Industry Track and Trace Regulations in the Rest of the World

Price: Starting at USD 3,000
Publish Date: 19 Apr 2022
Code: PT-2571
Research Type: Presentation
Pages: 22
Asset Visibility: Pharma Industry Track and Trace Regulations in the Rest of the World
Actionable Benefits

Actionable Benefits

  • Strategic planning for pharmaceutical vendors and distributors for changes in serialization regulations.
  • Gain insight into scale and scope of current regulations.
  • Guidance into proposed future regulatory changes.
Critical Questions Answered

Critical Questions Answered

  • What is the timeline for implementation of serialization regulations?
  • What are the key data standards and mandates for traceability?
  • How are international standards like GS1 leveraged in national regulations?
Research Highlights

Research Highlights

  • Focus on emerging markets (Brazil, South Africa, UAE, Saudi Arabia, and Turkey)
  • Identifies variation between region-level trends and country-level regulations.
  • Comparison and analysis of different levels of serialization.
Who Should Read This?

Who Should Read This?

  • Strategy planners and advisors within the pharmaceutical and supporting logistics industry.
  • Managers aiming to identify regulatory requirements of their operations.
  • For serialization software and hardware providers to assess regulatory impact on the pharmaceutical market.

Table of Contents

Executive Summary

Global Regulatory Environment

Regional Regulatory Environment

Key Objectives

National Regulations and International Standards

Summary of Proposed System

Compliance: Mandates versus Voluntary Best Practices 

Reporting Requirements

Suppliers and Third Parties Responsible for Track & Trace

Good Distribution Practices

Penalties and Fines

Scale and Scope of Implementations

Items Subject to Track & Trace

Future Amendments Proposed

Conclusion

Definitions and Abbreviations

 

Companies Mentioned